About 1 in 5 Paxlovid users experience rebound symptoms, according to the study

President Biden reiterated this week the promise that most Americans only need to get one annual booster vaccination against COVID-19, despite widespread skepticism from infectious disease experts, who believe the vaccine’s waning effectiveness will require more than one dose every 12 months. In California, Yosemite National Park officials have announced that the controversial reservation requirement enacted during the pandemic will no longer apply next year.

About 1 in 5 Paxlovid users experience rebound symptoms, according to the study

About 19% of COVID-19 patients who took the oral antiviral Paxlovid showed symptoms of rebound infection, according to a preprint paper released Tuesday by researchers at the Scripps Research Transitional Institute. In the study, conducted between August 4 and November 1, 2022, the team tracked the progress of 170 study participants who completed the 16-day procedures, 127 in the Paxlovid treatment group and 43 in the control group. The results showed that the virus rebound incidence was 14.2% in the Paxlovid group and 9.3% in the control group, while the COVID-19 symptom rebound incidence in the Paxlovid group (18.9 %) was higher than in the control group (7.0%). The researchers found that age, gender and previous illnesses played no role in the increased incidence.

“This preliminary report of our prospective study suggests that the rebound after elimination of test positivity or symptom resolution is higher than previously reported,” the authors wrote. “However, we observed a similar rebound rate in both the Paxlovid and control groups. To better understand the rebound phenomena, large studies with different participants and longer follow-up are needed.”

A clinical study by drugmaker Pfizer showed that Paxlovid reduced the risk of hospitalization and death from COVID-19 by 89%. The antiviral was made available under an emergency use authorization from the U.S. Food and Drug Administration in December 2021. Pfizer’s study estimated that about 1% of users experience rebound symptoms. Infectious disease experts believe the flare-up in COVID-19 symptoms after a full five-day course of Paxlovid treatment is likely due to insufficient drug exposure, according to research from UCSF.

SF offers a utility program for small businesses that have defaulted on city fees

San Francisco officials on Tuesday announced a program to support small businesses, mostly restaurants and food-processing businesses, impacted by the COVID-19 pandemic. Specifically, certain companies that have defaulted on Health Department license fees can continue to operate with valid licenses as long as they finalize a payment schedule by April 30, the mayor’s office said. “We know that COVID-19 has presented exceptional challenges for small business owners,” said Treasurer José Cisneros. “Giving businesses the ability to enter into payment plans will give small businesses the flexibility they need during this recovery period without sacrificing revenue.”

The press release said more than 1,000 companies have defaulted on fees totaling $2.6 million to the San Francisco Department of Health and $7 million in other taxes to the city. You can now pay them back in installments.

“This new law will be of tremendous help to small businesses, particularly immigrant and black businesses, who are facing other challenges alongside the impact of COVID,” said Connie Chan, District 1 Supervisor Paying fees in installments will help remove barriers to their jobs so they can be successful in San Francisco.”

According to the study, newer variants cause more symptoms and greater disorders

Newer coronavirus variants cause a greater variety of symptoms than their predecessors, according to a new study from Imperial College London. Researchers tracked transmission and symptoms in more than 1.5 million randomly selected adults, including 17,448 COVID-19 patients, from May 2020 to March 2022. About 76% of patients infected with BA.2, the predominant variant concluded at the time of the study, reported at least one of 26 symptoms, compared to 70% of those infected with BA.1, 63.8% of those with Delta, 54.7 % with alpha and 45% with the original wild-type strain. “Contrary to the perception that recent variants have become successively milder, omicron BA.2 was associated with reporting more symptoms and greater disruption in daily activities than BA.1,” the authors wrote.

At least 17.6% of those infected with BA.2 said their symptoms “severely” interfered with their ability to carry out daily activities, compared to 10.7% of those infected with BA.1 and 10.5% with Delta Persons. “With restrictions lifted and routine testing limited in many countries, monitoring the changing symptom profiles associated with SARS-CoV-2 infection and the impact on daily activities is becoming increasingly important,” they said.